{"product_id":"dyslipidemias-abhimanyu-garg-9781607614234","title":"Dyslipidemias: Pathophysiology, Evaluation and Management","description":"\u003cp\u003eChapter 1. Lipoprotein Physiology \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChapter 2. Epidemiology of Blood Lipids and Lipoproteins \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChapter 3. Lipoprotein(a)\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChapter 4. Lipoproteins and Cardiovascular Disease Risk \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChapter 6. Type 2 Diabetes Mellitus and Dyslipidemia \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eChapter 7. Type 1 Diabetes Mellitus and Dyslipidemia \u003c\/p\u003e \u003cp\u003eChapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome \u003c\/p\u003e \u003cp\u003eChapter 9. Dyslipidemia in HIV-infected Patients\u003c\/p\u003e \u003cp\u003eChapter 10. Monogenic Hypercholesterolemia \u003c\/p\u003e \u003cp\u003eChapter 11. Primary Hypertriglyceridemia \u003c\/p\u003e \u003cp\u003eChapter 12. Genetic Disorders of HDL Metabolism \u003c\/p\u003e \u003cp\u003eChapter 13. Sitosterolemia and Other Rare Sterol Disorders \u003c\/p\u003e \u003cp\u003eChapter 14. Genetic Abetalipoproteinemia \u0026amp; Hypobetalipoproteinemia \u003c\/p\u003e \u003cp\u003eChapter 15. Drug-induced Dyslipidemia \u003c\/p\u003e \u003cp\u003eChapter 16. Lipodystrophies and Dyslipidemias \u003c\/p\u003e \u003cp\u003eChapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies \u003c\/p\u003e \u003cp\u003eChapter 18. Perspectives on Cholesterol Guidelines\u003c\/p\u003e \u003cp\u003eChapter 19. Nutrition and Coronary Heart Disease Prevention \u003c\/p\u003e \u003cp\u003eChapter 20. Phytosterol Therapy \u003c\/p\u003e \u003cp\u003eChapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease \u003c\/p\u003e \u003cp\u003eChapter 22. Polyphenols for Cholesterol Management \u003c\/p\u003e \u003cp\u003eChapter 23 - Dietary Supplements for Cholesterol Management\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eChapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias \u003c\/p\u003e \u003cp\u003eChapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias \u003c\/p\u003e \u003cp\u003eChapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias \u003c\/p\u003e \u003cp\u003eChapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias\u003c\/p\u003e \u003cp\u003eChapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias \u003c\/p\u003e \u003cp\u003eChapter 29. Low Density Lipoprotein (LDL) Apheresis\u003c\/p\u003e \u003cp\u003eChapter 30. Novel Lipid Lowering Agents \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAuthor:\u003c\/b\u003e Abhimanyu Garg\u003cbr\u003e\u003cb\u003eISBN-10:\u003c\/b\u003e 1607614235\u003cbr\u003e\u003cb\u003eISBN-13:\u003c\/b\u003e 9781607614234\u003cbr\u003e\u003cb\u003ePublisher:\u003c\/b\u003e Humana\u003cbr\u003e\u003cb\u003eLanguage:\u003c\/b\u003e English\u003cbr\u003e\u003cb\u003ePublished:\u003c\/b\u003e 05\/22\/2015\u003cbr\u003e\u003cb\u003ePages:\u003c\/b\u003e 525\u003cbr\u003e\u003cb\u003eFormat:\u003c\/b\u003e Hardcover\u003cbr\u003e\u003cb\u003eWeight:\u003c\/b\u003e 2.54lbs\u003cbr\u003e\u003cb\u003eSize:\u003c\/b\u003e 10.00h x 7.00w x 1.19d","brand":"Abhimanyu Garg","offers":[{"title":"Hardcover","offer_id":43938712551679,"sku":"9781607614234","price":199.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/2982\/9887\/products\/img_a6808337-4260-462b-a5dd-b71fdc9f2d46.jpg?v=1681437296","url":"https:\/\/www.whiterainbookhouse.com\/products\/dyslipidemias-abhimanyu-garg-9781607614234","provider":"WR Book House","version":"1.0","type":"link"}